Probity Advisors Inc. Makes New $216,000 Investment in BioNTech SE (NASDAQ:BNTX)

Probity Advisors Inc. acquired a new position in BioNTech SE (NASDAQ:BNTX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 1,816 shares of the company’s stock, valued at approximately $216,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. GAMMA Investing LLC raised its stake in BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after purchasing an additional 111 shares in the last quarter. Covestor Ltd raised its stake in BioNTech by 47.2% in the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after purchasing an additional 133 shares in the last quarter. Midwest Professional Planners LTD. raised its stake in BioNTech by 7.2% in the 1st quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company’s stock worth $293,000 after purchasing an additional 212 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in BioNTech by 2.3% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 9,800 shares of the company’s stock worth $904,000 after purchasing an additional 223 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its stake in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after purchasing an additional 252 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Trading Down 2.8 %

Shares of NASDAQ BNTX opened at $114.47 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The firm has a 50 day moving average price of $103.95 and a two-hundred day moving average price of $94.05. The stock has a market cap of $27.21 billion, a P/E ratio of 228.94 and a beta of 0.24.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The business had revenue of $128.70 million during the quarter, compared to analyst estimates of $134.98 million. During the same quarter last year, the company posted ($0.86) earnings per share. The company’s revenue was down 23.3% compared to the same quarter last year. As a group, equities analysts forecast that BioNTech SE will post -3.04 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on BNTX shares. HSBC upped their price target on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Bank of America upped their price target on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, September 16th. HC Wainwright upped their price target on shares of BioNTech from $113.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, October 7th. UBS Group upped their price target on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a report on Wednesday, September 18th. Finally, Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and upped their price target for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. Five equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $131.92.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.